In head and neck squamous cell carcinoma (HNSCC) CSCs mouse models, targeting CD44 was shown to inhibit PI3K–4EBP1–SOX2 signaling and tumor growth and decrease the number of CSCs.50 This evidence concerns the gene SOX2 and head and neck squamous cell carcinoma.